The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease.
PMID: 30406036
2018
Frontiers in cellular and infection microbiology
Introduction: Similarly, the role of the precore mutation G1896A and the basal core promoter double mutation A1762T/G1764A in the progression of HBV-related liver diseases has been intensively studied (Kim et al.,).
Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-alpha-2a treatment in child patients.
Abstract: The baseline mutations A1762T/G1764A, C1913A, and T2003A/G or C2004T were correlated with non-response to therapy (P=0.025, P=0.036, P=0.032, respectively).
Clinical implication and viral mutation in basal core promoter/pre-core of hepatitis B virus C/D recombinant.
Abstract: Significantly higher levels of HBV DNA (6.7 ± 1.6 vs. 5.9 ± 1.5, p = 0.014), HBeAg (263.5 vs. 20.0, p = 0.013) and A1762T/G1764A double-mutations (81.0 vs. 61.8%, p = 0.018)
Abstract: The clonal frequencies of A1762T, G1764A, G1896A and A1846T were lower in patients with C/D than C2.
BCP/PC mutation prevalence and their association with HBV replication in HIV/HBV co-infected patients.
Abstract: All the 12 HCC-associated SNVs proved by meta-analysis were confirmed by NGS analysis, except for C1766T and T1768A which were mainly expressed in genotypes A and D, but including the subgroup analysis of A1762T.
[Monitoring by high-sensitivity HBV DNA assay during treatment in chronic hepatitis B e antigen negative patients].
Abstract: For 49 cases of HBeAg-negative patients, HBV B, C, B and C were mixed before tenofovir dipivoxil treatment, and C1653T, A1762T and G1764A mutation sites were detected in patients with D genotype.
Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
Abstract: Baseline pcG1896A mutation was identified in 51 (59.3%) patients, who were more commonly HBeAg-negative (P < .001) and had basal core promotor A1762T/G1764A mutations (P < .001).
The mutation of hepatitis B virus and the prognosis of hepatocellular carcinoma after surgery: a pilot study.
PMID: 29628773
2018
Cancer management and research
Introduction: The A1762T/G1764A BCP double mutation was associated with a hazard ratio (HR) of 1.73 for developing HCC.
Introduction: The most frequent BCP mutation is a double mutation involving an A to T substitution at nucleotide 1762 and a G to A substitution at nucleotide 1764.
Method: According to the sequencing outcome, HBV genotype and mutations (including A1752T/G, T1753C, G1757A, A1762T/G1764A, C1766T, T1768A, PMID: 29479565
2018
Hepatoma research
Introduction: By using the plasma samples from the members of the QBC, we found the A1762T/G1764A double mutation of the HBV basal core promoter (BCP) was frequently detected in HBV infected participants.
Introduction: However, the A1762T/G1764A double mutation alone was not sufficient to produce a statistically significant association with PLC.
Introduction: While A1762T/G1764A, C1653T, A799G, A987G, T1055A, pre-S deletion could be detected in the plasma long before P
Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants.
PMID: 29424069
2018
Journal of gastroenterology and hepatology
Abstract: A fibrosis score including Anti-hepatitis B e antibody, Basal core promoter (BCP) A1762T mutation, and Platelet count Index (named ABPI) was derived from the modeling cohort.
Abstract: CONCLUSIONS: We developed a transaminase-free fibrosis score (ABPI) utilizing basal core promoter A1762T data, which outperformed APRI and FIB-4.